<resources>
    <string name="app_name">Survey</string>
    <string name="Nationality">1. Where are you from?</string>
    <string name="bangladesh">Bangladesh</string>
    <string name="others">Others(Please Specify)</string>
    <string name="profession">2.What best describes your profession?</string>
    <string name="medical_oncologist">Medical Oncologist</string>
    <string name="radiation_oncologist">Radiation Oncologist</string>
    <string name="clinical_oncologist">Clinical Oncologist</string>
    <string name="others_please_specify">Others(Please specify)</string>
    <string name="post_graduate_student">Post graduate Student</string>
    <string name="general_physician">General Physician</string>
    <string name="clinical_practice">3.How many years have you been in clinical practice?</string>
    <string name="_5_years"><![CDATA[<5 Years]]></string>
    <string name="_5_10_years">5-10 Years</string>
    <string name="_10_20_years">10-20 Years</string>
    <string name="_20_years"><![CDATA[>20 Years]]></string>
    <string name="work_practice">4.What is the type of your practice currently work in?</string>
    <string name="_public">Public</string>
    <string name="_private">Private</string>
    <string name="both">Both</string>
    <string name="_20"><![CDATA[<20%]]></string>
    <string name="_20_30">20-30%</string>
    <string name="_30"><![CDATA[>30%]]></string>
    <string name="percentage">5.What percentage of your clinical practice is involved in treating patients with lung cancer?</string>
    <string name="lung_cancer_patient">6.How many new lung cancer patients do you see in a month?</string>
    <string name="_lessthan10"><![CDATA[<10]]></string>
    <string name="_10to20">10-20</string>
    <string name="greaterthan20"><![CDATA[>20]]></string>
    <string name="existing_lung_cancer_patient">7.How many existing lung cancer patients do you see in a month?</string>
    <string name="_50"><![CDATA[<50]]></string>
    <string name="_50to100">50-100</string>
    <string name="greaterthan100"><![CDATA[>100]]></string>
    <string name="common_histology">8.Which is the most common histology of lung cancer in your practice?</string>
    <string name="small_cell_lung_cancer">Small cell lung cancer</string>
    <string name="non_small_cell_lung_cancer_nos">Non small cell lung cancer NOS</string>
    <string name="adenocarcinoma">Adenocarcinoma</string>
    <string name="squamous_cell_carcinoma">Squamous cell carcinoma</string>
    <string name="adenosquamous_cell_carcinoma">Adenosquamous cell carcinoma</string>
    <string name="metastatic_lung_cancer">9.What percentage of the patients you see have metastatic lung cancer?</string>
    <string name="_30percentage"><![CDATA[<30%]]></string>
    <string name="_30_50">30-50%</string>
    <string name="_50percentage"><![CDATA[>50%]]></string>
    <string name="diagnostic_modality">10.What is the most common diagnostic modality of lung cancer you found in your day to day practice?</string>
    <string name="fnac">FNAC</string>
    <string name="fnab">FNAB</string>
    <string name="endo_bronchial_biopsy">Endo bronchial biopsy</string>
    <string name="endo_bronchial_lavage">Endo bronchial lavage</string>
    <string name="pleural_fluid_cytology">Pleural fluid cytology</string>
    <string name="core_biopsy">Core biopsy</string>
    <string name="lung_mass">11.What is the main challenge for not taking biopsy from lung mass?</string>
    <string name="not_needed_fnac_is_sufficient">Not needed, FNAC is sufficient</string>
    <string name="lack_of_expertise">Lack of expertise</string>
    <string name="cost_issue">Cost issue</string>
    <string name="patient_s_choice">Patient’s choice</string>
    <string name="lack_of_knowledge_about_it_s_importance">Lack of knowledge about it’s importance</string>
    <string name="staging_work_up">12.\tDo you offer PET-CT scan to each lung cancer patient for staging work up?</string>
    <string name="yes">Yes</string>
    <string name="no">No</string>
    <string name="metastatic_squamous">13.Which is your first consideration of chemotherapy in metastatic squamous cell carcinoma of lung?</string>
    <string name="paclitaxel_platinum">Paclitaxel +Platinum</string>
    <string name="pemetrexed_platinum">Pemetrexed+Platinum</string>
    <string name="vinorelbine_platinum">Vinorelbine +Platinum</string>
    <string name="gemcitabine_platinum">Gemcitabine+Platinum</string>
    <string name="docetaxel_platinum">Docetaxel+Platinum</string>
    <string name="metastatic_adeno">14.Which is your first consideration of chemotherapy in metastatic adeno carcinoma of lung?</string>
    <string name="cell_carcinoma">15.Which is your first consideration of chemotherapy in small cell carcinoma of lung?</string>
    <string name="paclitaxel_carboplatin">Paclitaxel +Carboplatin</string>
    <string name="cisplatin_etoposide">Cisplatin+Etoposide</string>
    <string name="irinotecan_carboplatin">Irinotecan+Carboplatin</string>
    <string name="preferred_TKI">16.If EGFR positive adeno ca lung, which is your preferred TKI?</string>
    <string name="erlotininb">Erlotininb</string>
    <string name="afatinib">Afatinib</string>
    <string name="gefitinib">Gefitinib</string>
    <string name="all_are_same_in_terms_of_efficacy">All are same in terms of efficacy</string>
    <string name="EGFR_testing">17.What is your preferred EGFR testing procedure?</string>
    <string name="egfr_testing_from_biopsy_material">EGFR testing from biopsy material</string>
    <string name="egfr_testing_from_liquid_biopsy">EGFR testing from liquid biopsy</string>
    <string name="TKI_blindly">18.Do you use TKI blindly in lung cancer?</string>
    <string name="sometimes">Sometimes</string>
    <string name="metastatic_NSCLC">19.What is your preferred 1st line chemotherapy regimen if the diagnosis is metastatic NSCLC,not otherwise specified?</string>
    <string name="ECOG_2">20.Do you use combination chemotherapy in metastatic lung cancer in ECOG 2 performance status?</string>
    <string name="immunotherapy">21.Do u think that immunotherapy is also an important modality of lung cancer?</string>
    <string name="treatment_algorithm">22.\tWhat do you think that these immunotherapeutic drugs should be fit in which part of treatment algorithm (if cost is not an issue)?</string>
    <string name="maintenance">Maintenance</string>
    <string name="adjuvant">Adjuvant</string>
    <string name="_3rd_line">3rd line</string>
    <string name="_2nd_line">2nd line</string>
    <string name="_1st_line">1st line</string>
    <string name="Lung_cancer_management">23.Any comment or suggestion regarding Lung cancer management in Bangladesh.</string>
    <string name="input1">1.Where are you from?</string>
    <string name="input2">2.What best describes your profession?</string>
    <string name="input3">3.How many years have you been in clinical practice?</string>
    <string name="input4">4.What is the type of your practice currently work in?</string>
    <string name="input5">5.What percentage of your clinical practice is involved in treating patients with lung cancer?</string>
    <string name="input6">6.How many new lung cancer patients do you see in a month?</string>
    <string name="input7">7.How many existing lung cancer patients do you see in a month?</string>
    <string name="input8">8.Which is the most common histology of lung cancer in your practice?</string>
    <string name="input9">9.What percentage of the patients you see have metastatic lung cancer?</string>
    <string name="input10">10.What is the most common diagnostic  modality of lung cancer you found in your day to day practice?</string>
    <string name="input11">11.What is the main challenge for not taking biopsy from lung mass?/</string>
    <string name="input12">12.Do you offer PET-CT scan to each lung cancer patient for staging work up?</string>
    <string name="input13">13.Which is your first consideration of chemotherapy in metastatic squamous cell carcinoma of lung?</string>
    <string name="input14">14.Which is your first consideration of chemotherapy in metastatic adeno carcinoma of lung?</string>
    <string name="input15">15.Which is your first consideration of chemotherapy in small cell carcinoma of lung?</string>
    <string name="input16">16.If EGFR positive adeno ca lung, which is your preferred TKI?</string>
    <string name="input17">17.What is your preferred EGFR testing procedure?</string>
    <string name="input18">18.Do you use TKI blindly in lung cancer?</string>
    <string name="input19">19.What is your preferred 1st line chemotherapy regimen if the diagnosis is metastatic NSCLC,not otherwise specified?</string>
    <string name="input20">20.Do you use combination chemotherapy in metastatic lung cancer in ECOG 2 performance status?</string>
    <string name="input21">21.Do u think that immunotherapy is also an important modality of lung cancer?</string>
    <string name="input22">22.What do you think that these immunotherapeutic drugs should be fit in which part of treatment algorithm (if cost is not an issue)</string>
    <string name="input23">23.Any comment or suggestion regarding Lung cancer management in Bangladesh.</string>
    <string name="save">Save</string>

</resources>
